Week In Review: MGI Tech Raises $200 Million To Manufacture Genomic Sequencing Machines

• MGI Tech a Shenzhen maker of gene sequencing machines and a subsidiary of genomics company BGI, completed an A funding of more than $200 million;
• Xynomic Pharma closed its business combination with Bison Capital Acquisition, becoming a wholly-owned subsidiary of BCAC in a $191.6 million deal; 
• HanX Biopharma, a China oncology company, in-licensed China rights to a Phase III candidate for myelodysplastic syndromes from Onconova in a $51.5 million agreement;
• AnHeart Therapeutics of Hangzhou raised $14.6 million to develop in-licensed oncology drugs in a Series A round from Decheng Capital;
• US-based Leads Biolabs, a fully-owned subsidiary of Nanjing Leads Biolabs, granted Pneuma a license to develop inhaled versions of Leads' immuno-oncology candidates; 
• China's Winhealth Pharma in-licensed greater China rights for two FDA approved pain management drugs from Cumberland Pharma; 
• Shenzhen Mindray signed an agreement allowing it to use Masimo's technology for noninvasive, continuous measurement of pulse oximetry;
• Shanghai ChemPartner, a China CRO, installed Berkeley Lights' Beacon® Optofluidic platform to offer B Cell antibody discovery services;

Company News

• WuXi Biologics, a China biologics CRO/CMO, began building a large manufacturing center for innovative biologics in Chengdu;

Trials and Approvals

• Suzhou's Innovent and its partner Lilly announced their anti-CD20 biosimilar to Rituxan met its primary endpoints in two China clinical trials.

Disclosure: None

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.